Role of physiological intestinal water in oral absorption

AAPS Journal

Volumn 11, Issue 2, 2009, Pages 277-285

  Sutton, Steven C ^a,b  

^a UNIVERSITY OF NEW ENGLAND   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Biopharmaceutics; Intestinal water; Modeling; Simulation

Indexed keywords

CJ 13610; GASTROINTESTINAL AGENT; NIFEDIPINE; SERTRALINE; TROVAFLOXACIN; UNCLASSIFIED DRUG; WATER;

ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG METABOLISM; DRUG RELEASE; DRUG SOLUBILITY; HUMAN; INTESTINE FLUID; INTESTINE MUCOSA PERMEABILITY; LARGE INTESTINE WATER VOLUME; MAXIMUM PLASMA CONCENTRATION; PRECIPITATION; SMALL INTESTINE WATER VOLUME; VOLUMETRY;

ANIMALS; BIOPHARMACEUTICS; BODY WATER; HUMANS; INTESTINAL ABSORPTION; INTESTINE, LARGE; INTESTINE, SMALL; INTESTINES; MODELS, BIOLOGICAL; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; SOLUBILITY;

EID: 68249133855     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-009-9087-2     Document Type: Article

References (32)

1. K. C. Waterman, and S. C. Sutton. A computational model for particle size influence on drug absorption during controlled-release colonic delivery. J. Control. Release. 86:293-304 (2003).
2. C. Lipinski. Drug solubility in water and dimethylsulfoxide. In R. Mannhold (ed.), Molecular Drug Properties Measurement and Prediction, Wiley-VCH, Weinheim, 2008, p. 258.
3. J. Cummings, J. Banwell, T. Segal, N. Coleman, H. Englyst, and G. Macfarlane. The amount and composition of large bowel contents in man. Gastroenterolgy. 98: A408 (1990).
4. A. D. Badley, M. Camilleri, and M. K. O'Connor. Noninvasive measurement of human ascending colon volume. Nucl. Med. Common. 14:485-489 (1993).
5. C. L. Hoad, L. Marciani, S. Foley, J. J. Totman, J. Wright, D. Bush, E. F. Cox, E. Campbell, R. C. Spiller, and P. A. Gowland. Non-invasive quantification of small bowel water content by MRI: A validation study. Phys. Med. Biol. 52:6909-6922 (2007).
6. L. Marciani, S. Foley, C. Hoad, E. Campbell, J. Totman, E. Cox, P. Gowland, and R. C. Spiller. Magnetic resonance imaging of abnormalities in diarrhoea-predominant Irritable Bowel Syndrome fasting and after a bran-containing meal, United European Gastroenterology Week (UEGW), Paris, 2007.
7. L. Marciani, S. Foley, C. Hoad, E. Campbell, J. Totman, A. Armstrong, P. Manby, P. A. Gowland, and R. Spiller. Effects of Ondansetron on small bowel water content: A magnetic resonance imaging study, United European Gastroenterology Week (UEGW), Paris, 2007.
8. C. Schiller, C. -P. Frohlich, T. Giessmann, W. Siegmund, H. Monnikes, N. Hosten, and W. Weitschies. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment Pharmacol. Ther. 22: 971-979 (2005).
9. S. Bhattachar, L. Deschenes, and J. Wesley. Solubility: It's not just for physical chemists. Drug Discov. Today. 11:1012-1018 (2006).
10. K. Box, G. Völgyi, E. Baka, M. Stuart, K. Takács-Novák, and J. Comer. Equilibrium versus kinetic measurements of aqueous solubility, and the ability of compounds to supersaturate in solution - a validation study. J. Pharm. Sci.c 95:1298-1307 (2006).
11. M. Tubic, D. Wagner, H. Spahn-Langguth, M. Bolger, and P. Langguth. In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect. Pharm. Res. 23:1712-1720 (2006).
12. L. X. Yu. An integrated model for determining causes of poor oral drug absorption. Pharm Res. 16:1883-1887 (1999).
13. A. S. Noyes, and W. R. Whitney. The rate of solution of solid substances in their own solutions. J. Amer. Chem. Soc. 19:930-934 (1897).
14. R. S. Obach, L. M. Cox, and L. Tremaine. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: An in vitro study. Drug Metab. Dispos. 33:262-270 (2005).
15. S. -Y. Yee, and W. -W. Day. Applications of Caco-2 cells in drug discovery and development. In T. F. Woolf (ed.), Handbook Of Drug Metabolism, Marcel Dekker, New York, 1999, pp. 507-522.
16. S. C. Sutton, M. T. S. Rinaldi, and K. E. Vukovinsky. Comparison of the gravimetric, phenol red and 14C-PEG-3350 methods to determine water absorption in the rat single pass intestinal perfusion model. AAPS Pharm. Sci. 3:aRticle 25 (2001).
17. S. C. Sutton, M. T. S. Rinaldi, J. M. McCarthy, and K. E. Vukovinsky. A statistical method for the determination of absorption rate constant estimated using the rat single pass intestinal perfusion model and multiple linear regression. J. Pharm. Sci. 91:1046-1053 (2002).
18. L. R. Johnson (ed.). Physiology of the gastrointestinal tract, Raven, New York, 1994.
19. J. Fordtran, and J. Dietschy. Water and electrolyte movement in the intestine. Gastroenterolgy. 50:263-285 (1968).
20. S. D. Mithani, V. Bakatselou, C. N. TenHoor, and J. B. Dressman. Estimation of the increase in solubility of drugs as a function of bile salt concentration. Pharm. Res. 13:163-167 (1996).
21. E. Kostewicz, R. Becker, U. Brauns, and J. Dressman. In vitro model to predict the precipitation of a poorly soluble weak base following its transition out of the stomach and into the intestine. AAPS Pharm. Sci. 1:S-491 (1999).
22. M. D. Likar, J. Bordner, D. M. Rescek, and T. R. Sharp. Sertraline (L)-Lactate: Comprehensive Profile. Profiles of drug substances, excipients and related methodology, Vol. 30, Elsevier, Boston, 2003, pp. 185-234.
23. D. Friesen, S. Herbig, R. Shanker, and J. West. PCT Int. Appl. WO 99 01121 sertraline salts and sustained-release dosage forms of sertraline. Chem. Abs. 130:115031 (1999).
24. B. K. Koe, A. Weissman, W. M. Welch, and R. G. Browne. Sertraline, 1S,4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1 -naphthylamine, a new uptake inhibitor with selectivity for serotonin. J. Pharmacol. Exp. Ther. 226:686-700 (1983).
25. B. A. Hamelin, J. Turgeon, F. Vallee, P. -M. Belanger, F. Paquet, and M. LeBel. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin(ast). Clin. Pharmacol. Ther. 60:512-521 (1996).
26. M. Nokano. Places of emulsions in drug delivery. Adv. Drug Deliv. Rev. 45:1-4 (2000).
27. A. T. M. Serajuddin. Salt formation to improve drug solubility. Adv. Drug Deliv. Rev. 59:603-616 (2007).
28. B. S. Schug, E. Brendel, D. Wolf, M. Wonnemann, M. Wargenau, and H. H. Blume. Formulation-dependent food effects demonstrated for nifedipine modified-release preparations marketed in the European Union. Eur. J. Pharm. Sci. 15:279-285 (2002).
29. D. R. Swanson, B. L. Barclay, P. S. L. Wong, and F. Theeuwes. Nifedipine gastrointestinal therapeutic system. Am. J. Med. 83:3-9 (1987).
30. T. Foster, S. Hamann, V. Richards, P. Bryant, D. Graves, and R. McAllister. Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects. J. Clin. Pharmacol. 23:161-170 (1983).
31. M. Chung, D. Reitberg, M. Gaffney, and W. Singleton. Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system. Am. J. Med. 83:10-14 (1987).
32. H. Bode, E. Brendel, G. Ahr, U. Fuhr, and S. Harder. Investigation of nifedipine absorption in different regions of the human git after simultaneous administration of 13C and 12C nifedipine. Eur. J. Clin. Pharmacol. 50:195-201 (1996).